Drugs / Re-Join®
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02162693 | Nov 2013 → May 2016 | osteoarthritis, knee | Shanghai AbelZeta Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Re-Join | “Re-Join® comprises in vitro expanded haMPCs from adipose tissue of patients combined with cell suspension solution.” PMID 31113476 ↗ May 2019 |
| Route | Other | “Patients with Kellgren-Lawrence grade 1-3 knee OA were recruited from two centers and randomized to receive intra-articular injection of Re-Join® or HA.” PMID 31113476 ↗ May 2019 |